ADAR1 may be involved in the proliferation of acute myeloid leukemia cells via regulation of the Wnt pathway

References

• Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood. 2011;117(8):2307–2318. doi:10.1182/blood-2010-10-26560321098397
   PubMed Web of Science ®Google Scholar
• Khaled S, Al MM, Marcucci G. Acute myeloid leukemia: biologic, prognostic, and therapeutic insights. Oncology (Williston Park). 2016;30(4):318–329.27085330
   PubMed Web of Science ®Google Scholar
• Hatfield KJ, Reikvam H, Bruserud Ø. Identification of a subset of patients with acute myeloid leukemia characterized by long-termin vitro proliferation and altered cell cycle regulation of the leukemic cells. Expert Opin Ther Tar. 2014;18(11):1237–1251. doi:10.1517/14728222.2014.957671
   PubMed Web of Science ®Google Scholar
• Feldman EJ. Novel therapeutics for therapy-related acute myeloid leukemia: 2014. Clin Lymphoma Myeloma Leuk. 2015;15:S91–S93. doi:10.1016/j.clml.2015.02.03126297287
   PubMed Web of Science ®Google Scholar
• Eriksson A, Lennartsson A, Lehmann S. Epigenetic aberrations in acute myeloid leukemia: early key events during leukemogenesis. Exp Hematol. 2015;43(8):609–624. doi:10.1016/j.exphem.2015.05.00926118500
   PubMed Web of Science ®Google Scholar
• Sanchez M, Levine RL, Rampal R. Integrating genomics into prognostic models for AML. Semin Hematol. 2014;51(4):298–305. doi:10.1053/j.seminhematol.2014.08.00225311742
   PubMed Web of Science ®Google Scholar
• Wang Q, Khillan J, Gadue P, Nishikura K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science. 2000;290(5497):1765–1768. doi:10.1126/science.290.5497.176511099415
   PubMed Web of Science ®Google Scholar
• Cachat A, Alais S, Chevalier SA, et al. ADAR1 enhances HTLV-1 and HTLV-2 replication through inhibition of PKR activity. Retrovirology. 2014;11:93. doi:10.1186/s12977-014-0093-925389016
   PubMed Web of Science ®Google Scholar
• Qiao JJ, Chan TH, Qin YR, Chen L. ADAR1: a promising new biomarker for esophageal squamous cell carcinoma? Expert Rev Anticancer Ther. 2014;14(8):865–868. doi:10.1586/14737140.2014.92859524928581
   PubMed Web of Science ®Google Scholar
• Hartner JC, Walkley CR, Lu J, Orkin SH. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol. 2009;10(1):109–115. doi:10.1038/ni.168019060901
   PubMed Web of Science ®Google Scholar
• Chan THM, Lin CH, Qi L, et al. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014;63(5):832–843. doi:10.1136/gutjnl-2012-30403723766440
   PubMed Web of Science ®Google Scholar
• Anadon C, Guil S, Simo-Riudalbas L, et al. Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene. 2016;35(33):4422. doi:10.1038/onc.2016.27
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang H, Lin W, Shuai P. ADAR1 overexpression is associated with cervical cancer progression and angiogenesis. Diagn Pathol. 2017;12(1):12. doi:10.1186/s13000-017-0600-028109322
   PubMedGoogle Scholar
• Nemlich Y, Greenberg E, Ortenberg R, et al. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest. 2013;123(6):2703–2718. doi:10.1172/JCI6298023728176
   PubMed Web of Science ®Google Scholar
• Rossetti C, Picardi E, Ye M, et al. RNA editing signature during myeloid leukemia cell differentiation. Leukemia. 2017;31(12):2824–2832. doi:10.1038/leu.2017.13428484266
   PubMed Web of Science ®Google Scholar
• Ma CH, Chong JH, Guo Y, et al. Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias. Biochem Biophys Res Commun. 2011;406(2):245–251. doi:10.1016/j.bbrc.2011.02.02521316340
   PubMed Web of Science ®Google Scholar
• National comprehensive cancer network: NCCN categories of evidence and consensus., 2018.
   Google Scholar
• Steinman RA, Yang Q, Gasparetto M, et al. Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice. Int J Cancer. 2013;132(8):1741–1750. doi:10.1002/ijc.2785122987615
   PubMed Web of Science ®Google Scholar
• Dou N, Yu S, Ye X, Yang D, Li Y, Gao Y. Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling. Oncotarget. 2016;7(52):86161–86173. doi:10.18632/oncotarget.1335427863387
   PubMedGoogle Scholar
• Qin YR, Qiao JJ, Chan THM, et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res. 2014;74(3):840–851. doi:10.1158/0008-5472.CAN-13-254524302582
   PubMed Web of Science ®Google Scholar
• Gu Y, Masiero M, Banham AH. Notch signaling: its roles and therapeutic potential in hematological malignancies. Oncotarget. 2016;7(20):29804–29823. doi:10.18632/oncotarget.777226934331
   PubMedGoogle Scholar
• Zhou J, Ching YQ, Chng WJ. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target. Oncotarget. 2015;6(8):5490–5500. doi:10.18632/oncotarget.354525823927
   PubMed Web of Science ®Google Scholar
• Carneiro BA, Kaplan JB, Altman JK, Giles FJ, Platanias LC. Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. Cancer Biol Ther. 2015;16(5):648–656. doi:10.4161/15384047.2014.98754825801978
   PubMed Web of Science ®Google Scholar
• Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C. The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia. 2007;21(8):1638–1647. doi:10.1038/sj.leu.240473217554387
   PubMed Web of Science ®Google Scholar
• Qiu W, Wang X, Buchanan M, et al. ADAR1 is essential for intestinal homeostasis and stem cell maintenance. Cell Death Dis. 2013;4(4):e599. doi:10.1038/cddis.2013.12523598411
   PubMedGoogle Scholar
• Ge X, Wang X. Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol. 2010;3:33. doi:10.1186/1756-8722-3-5020843302
   PubMed Web of Science ®Google Scholar